UB Paderborn / Katalog / Suche / in CDI

1 – 25 von 89

Sortiert nach

Results of PREVENT III: A multicenter, randomized trial of edifoligide for the prevention of vein graft failure in lower extremity bypass surgery

Journal of vascular surgery, 2006-04, Vol.43 (4), p.742-751.e1

2006

Volltextzugriff (PDF)

The design and rationale for the Acute Medically Ill Venous Thromboembolism Prevention with Extended Duration Betrixaban (APEX) study

The American heart journal, 2014-03, Vol.167 (3), p.335-341

2014

Volltextzugriff (PDF)

Rationale and design of the Acute Study of Clinical Effectiveness of Nesiritide in Decompensated Heart Failure Trial (ASCEND-HF)

The American heart journal, 2009-02, Vol.157 (2), p.271-277

2009

Volltextzugriff (PDF)

Edifoligide and long-term outcomes after coronary artery bypass grafting: PRoject of Ex-vivo Vein graft ENgineering via Transfection IV (PREVENT IV) 5-year results

The American heart journal, 2012-09, Vol.164 (3), p.379-386.e1

2012

Volltextzugriff (PDF)

Efficacy and safety of edifoligide, an E2F transcription factor decoy, for prevention of vein graft failure following coronary artery bypass graft surgery: PREVENT IV: a randomized controlled trial

JAMA : the journal of the American Medical Association, 2005-11, Vol.294 (19), p.2446

2005

Volltextzugriff (PDF)

Addressing missing data in clinical trials

Annals of internal medicine, 2011-07, Vol.155 (2), p.135

2011

Volltextzugriff (PDF)

Platelet glycoprotein IIb/IIIa integrin blockade with eptifibatide in coronary stent intervention: the ESPRIT trial: a randomized controlled trial

JAMA : the journal of the American Medical Association, 2001-05, Vol.285 (19), p.2468

2001

Volltextzugriff (PDF)

Relationship of creatine kinase-myocardial band release to Thrombolysis in Myocardial Infarction perfusion grade after intracoronary stent placement: An ESPRIT substudy

The American heart journal, 2002-01, Vol.143 (1), p.106-110

2002

Volltextzugriff (PDF)

Relation of Early Saphenous Vein Graft Failure to Outcomes Following Coronary Artery Bypass Surgery

The American journal of cardiology, 2005-11, Vol.96 (9), p.1254-1259

2005

Volltextzugriff (PDF)

Pharmacodynamics and pharmacokinetics of higher-dose, double-bolus eptifibatide in percutaneous coronary intervention

Circulation (New York, N.Y.), 2001-07, Vol.104 (4), p.406-411

2001

Volltextzugriff (PDF)

The PRoject of ex-vivo vein graft ENgineering via transfection IV (PREVENT IV) trial : Study rationale, design, and baseline patient characteristics

The American heart journal, 2005-10, Vol.150 (4), p.643-649

2005

Volltextzugriff (PDF)

Immediate coronary artery bypass surgery after platelet inhibition with eptifibatide: results from PURSUIT

The Annals of thoracic surgery, 2000-09, Vol.70 (3), p.866-871

2000

Volltextzugriff (PDF)

Clinical pharmacology of higher dose eptifibatide in percutaneous coronary intervention (the PRIDE study)

The American journal of cardiology, 2001-11, Vol.88 (10), p.1097-1102

2001

Volltextzugriff (PDF)

Early percutaneous coronary intervention, platelet inhibition with eptifibatide, and clinical outcomes in patients with acute coronary syndromes

Circulation (New York, N.Y.), 2000-02, Vol.101 (7), p.751-757

2000

Volltextzugriff (PDF)

Is glycoprotein IIb/IIIa antagonism as effective in women as in men following percutaneous coronary intervention? Lessons from the ESPRIT study

Journal of the American College of Cardiology, 2002-09, Vol.40 (6), p.1085-1091

2002

Volltextzugriff (PDF)

Design and Rationale of the PREVENT III Clinical Trial: Edifoligide for the Prevention of Infrainguinal Vein Graft Failure

Vascular and endovascular surgery, 2005-01, Vol.39 (1), p.15-23

2005

Volltextzugriff (PDF)

Design and methodology of the ESPRIT trial: Evaluating a novel dosing regimen of eptifibatide in percutaneous coronary intervention

The American heart journal, 2000-12, Vol.140 (6), p.834-839

2000

Volltextzugriff (PDF)

Ethics and Equipoise: Rationale for a Placebo-Controlled Study Design of Platelet Glycoprotein IIb/IIIa Inhibition in Coronary Intervention

Journal of interventional cardiology, 2003-04, Vol.16 (2), p.97-105

2003

Volltextzugriff (PDF)

Edifoligide and Long-Term Outcomes After Coronary Artery Bypass Grafting: PREVENT IV 5-Year Results

The American heart journal, 2012-09, Vol.164 (3), p.379-386.e1

2012

Volltextzugriff (PDF)

Inhibition of endotoxin-induced cytokine release and neutrophil activation in humans by use of recombinant bactericidal/permeability-increasing protein

The Journal of infectious diseases, 1995-07, Vol.172 (1), p.144

1995

Volltextzugriff (PDF)

The PRoject of Ex-vivo Vein graft ENgineering via Transfection IV (PREVENT IV) trial

The American heart journal, 2005-10, Vol.150 (4), p.643-649

2005

Volltextzugriff (PDF)

Nonimmunogenicity of eptifibatide, a cyclic heptapeptide inhibitor of platelet glycoprotein IIb–IIIa

Clinical therapeutics, 1999, Vol.21 (1), p.128-137

1999

Volltextzugriff (PDF)

Is glycoprotein IIb/IIIa antagonism as effective in women as in men following percutaneous coronary intervention?

Journal of the American College of Cardiology, 2002-09, Vol.40 (6), p.1085-1091

2002

Volltextzugriff (PDF)

Relationship of creatine kinase-myocardial bond release to Thrombolysis in Myocardial Infarction perfusion grade after intracoronary stent placement: An ESPRIT substudy

The American heart journal, 2002, Vol.143 (1), p.106-110

2002

Volltextzugriff (PDF)

Results of PREVENT III: A multicenter, randomized trial of edifoligide for the prevention of vein graft failure in lower extremity bypass surgery. Commentary

Journal of vascular surgery, 2006, Vol.43 (4), p.742-751

2006

Volltextzugriff (PDF)

1 – 25 von 89

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(82)
Mit Volltextzugriff
(75)

Publikationsform

Sprache

Erscheinungsjahr

n.n

Thema

Science & Technology
(61)
Life Sciences & Biomedicine
(49)
Humans
(34)
Biological And Medical Sciences
(29)
Medical Sciences
(25)
Female
(18)
Male
(18)
Cardiovascular System & Cardiology
(17)
Middle Aged
(16)
Cardiac & Cardiovascular Systems
(14)
Aged
(11)
Pharmacology. Drug Treatments
(10)
Physical Sciences
(9)
Treatment Outcome
(9)
Cardiology. Vascular System
(8)
Platelet Glycoprotein Gpiib-Iiia Complex - Antagonists & Inhibitors
(8)
Surgery
(8)
Time Factors
(8)
Adult
(7)
Animals
(7)

15 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

... seit 30 Tagen
(1)

Menü

Weitere Dienste

Einstellungen

Results of PREVENT III: A multicenter, randomized trial of edifoligide for the prevention of vein graft failure in lower extremity bypass surgery

The design and rationale for the Acute Medically Ill Venous Thromboembolism Prevention with Extended Duration Betrixaban (APEX) study

Rationale and design of the Acute Study of Clinical Effectiveness of Nesiritide in Decompensated Heart Failure Trial (ASCEND-HF)

Edifoligide and long-term outcomes after coronary artery bypass grafting: PRoject of Ex-vivo Vein graft ENgineering via Transfection IV (PREVENT IV) 5-year results

Efficacy and safety of edifoligide, an E2F transcription factor decoy, for prevention of vein graft failure following coronary artery bypass graft surgery: PREVENT IV: a randomized controlled trial

Addressing missing data in clinical trials

Platelet glycoprotein IIb/IIIa integrin blockade with eptifibatide in coronary stent intervention: the ESPRIT trial: a randomized controlled trial

Relationship of creatine kinase-myocardial band release to Thrombolysis in Myocardial Infarction perfusion grade after intracoronary stent placement: An ESPRIT substudy

Relation of Early Saphenous Vein Graft Failure to Outcomes Following Coronary Artery Bypass Surgery

Pharmacodynamics and pharmacokinetics of higher-dose, double-bolus eptifibatide in percutaneous coronary intervention

The PRoject of ex-vivo vein graft ENgineering via transfection IV (PREVENT IV) trial : Study rationale, design, and baseline patient characteristics

Immediate coronary artery bypass surgery after platelet inhibition with eptifibatide: results from PURSUIT

Clinical pharmacology of higher dose eptifibatide in percutaneous coronary intervention (the PRIDE study)

Early percutaneous coronary intervention, platelet inhibition with eptifibatide, and clinical outcomes in patients with acute coronary syndromes

Is glycoprotein IIb/IIIa antagonism as effective in women as in men following percutaneous coronary intervention? Lessons from the ESPRIT study

Design and Rationale of the PREVENT III Clinical Trial: Edifoligide for the Prevention of Infrainguinal Vein Graft Failure

Design and methodology of the ESPRIT trial: Evaluating a novel dosing regimen of eptifibatide in percutaneous coronary intervention

Ethics and Equipoise: Rationale for a Placebo-Controlled Study Design of Platelet Glycoprotein IIb/IIIa Inhibition in Coronary Intervention

Edifoligide and Long-Term Outcomes After Coronary Artery Bypass Grafting: PREVENT IV 5-Year Results

Inhibition of endotoxin-induced cytokine release and neutrophil activation in humans by use of recombinant bactericidal/permeability-increasing protein

The PRoject of Ex-vivo Vein graft ENgineering via Transfection IV (PREVENT IV) trial

Nonimmunogenicity of eptifibatide, a cyclic heptapeptide inhibitor of platelet glycoprotein IIb–IIIa

Is glycoprotein IIb/IIIa antagonism as effective in women as in men following percutaneous coronary intervention?

Relationship of creatine kinase-myocardial bond release to Thrombolysis in Myocardial Infarction perfusion grade after intracoronary stent placement: An ESPRIT substudy

Results of PREVENT III: A multicenter, randomized trial of edifoligide for the prevention of vein graft failure in lower extremity bypass surgery. Commentary

Suchergebnisse filtern